secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000899923-24-000025
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics Q1 revenue $202M (+12% YoY), positive adjusted EBITDA $4M, reiterates FY guidance
--------------------------------------------------------------------------------

- Q1 revenue $202.2M (+12% YoY); GAAP net loss narrowed to $26M from $55M.
- Adjusted EPS -$0.01 vs -$0.21 YoY; positive adjusted EBITDA $4M vs -$19M.
- Revenue growth driven by Prenatal (+22%), Pharmacogenomics (+21%), Hereditary Cancer (+16%).
- Announced sale of EndoPredict to Eurobio Scientific; retains U.S. license.
- Reiterates FY2024 guidance: revenue $820-840M, adjusted EBITDA $20-30M, adjusted EPS $0.00-$0.05.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992324000025/0000899923-24-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992324000025/mygn-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000899923-24-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer